Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
72 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Keratitis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Keratitis - Pipeline Review, H2 2014', provides an overview of the Keratitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Keratitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Keratitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Keratitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Keratitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Keratitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Keratitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Keratitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Keratitis Overview 7 Therapeutics Development 8 Pipeline Products for Keratitis - Overview 8 Pipeline Products for Keratitis - Comparative Analysis 9 Keratitis - Therapeutics under Development by Companies 10 Keratitis - Therapeutics under Investigation by Universities/Institutes 12 Keratitis - Pipeline Products Glance 13 Clinical Stage Products 13 Early Stage Products 14 Keratitis - Products under Development by Companies 15 Keratitis - Products under Investigation by Universities/Institutes 16 Keratitis - Companies Involved in Therapeutics Development 17 Adamis Pharmaceuticals Corporation 17 Cellceutix Corporation 18 Dompe Farmaceutici S.p.A. 19 Kala Pharmaceuticals, Inc. 20 Peregrine Pharmaceuticals, Inc. 21 RegeneRx Biopharmaceuticals, Inc. 22 Sirnaomics, Inc. 23 The Medicines Company 24 Keratitis - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 brilacidin - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 C-31G - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 IBN-1 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 loteprednol etabonate - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 moxifloxacin hydrochloride - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 PGN-632 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 PIM-45 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Recombinant Human Nerve Growth Factor - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 RGN-259 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Small Molecules to Inhibit ATM for Herpes Keratitis - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 STP-601 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 targocil - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 tigecycline - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Keratitis - Recent Pipeline Updates 52 Keratitis - Dormant Projects 66 Keratitis - Product Development Milestones 67 Featured News & Press Releases 67 Oct 20, 2014: RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy 67 Jul 23, 2014: Dompe announces the Food and Drug Administration has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 68 Nov 04, 2013: Cellceutix to Pursue Significant Conjuctivitis and Kerititis Ocular Markets With Novel Antibiotic Brilacidin 68 Feb 14, 2013: Dompe Announces Enrollment Of First Patient In First International Clinical Trial Of rhNGF For Treatment Of Neurotrophic Keratitis 69 Appendix 71 Methodology 71 Coverage 71 Secondary Research 71 Primary Research 71 Expert Panel Validation 71 Contact Us 72 Disclaimer 72
List of Tables Number of Products under Development for Keratitis, H2 2014 8 Number of Products under Development for Keratitis - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 11 Number of Products under Investigation by Universities/Institutes, H2 2014 12 Comparative Analysis by Clinical Stage Development, H2 2014 13 Comparative Analysis by Early Stage Development, H2 2014 14 Products under Development by Companies, H2 2014 15 Products under Investigation by Universities/Institutes, H2 2014 16 Keratitis - Pipeline by Adamis Pharmaceuticals Corporation, H2 2014 17 Keratitis - Pipeline by Cellceutix Corporation, H2 2014 18 Keratitis - Pipeline by Dompe Farmaceutici S.p.A., H2 2014 19 Keratitis - Pipeline by Kala Pharmaceuticals, Inc., H2 2014 20 Keratitis - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2014 21 Keratitis - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2014 22 Keratitis - Pipeline by Sirnaomics, Inc., H2 2014 23 Keratitis - Pipeline by The Medicines Company, H2 2014 24 Assessment by Monotherapy Products, H2 2014 25 Number of Products by Stage and Target, H2 2014 27 Number of Products by Stage and Mechanism of Action, H2 2014 29 Number of Products by Stage and Route of Administration, H2 2014 31 Number of Products by Stage and Molecule Type, H2 2014 33 Keratitis Therapeutics - Recent Pipeline Updates, H2 2014 52 Keratitis - Dormant Projects, H2 2014 66
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
